Topical vs Oral Finasteride: Results and Side Effects

Oral finasteride has been the standard 5-alpha reductase inhibitor for androgenetic alopecia since its FDA approval in 1997. It works. But a small percentage of users report sexual side effects, and that risk drives many men to look for alternatives that keep the drug at the scalp rather than flooding the bloodstream. Topical finasteride is the most direct answer to that concern. It uses the same molecule, applied differently, with the goal of concentrating DHT suppression where it matters most while reducing systemic exposure. The research since 2020 has made the comparison clearer than it used to be.

Track your finasteride response with structure

BaldingAI helps you log monthly photos, side-effect notes, and adherence data so your topical-vs-oral decision is based on your own evidence.

Use the BaldingAI hair tracking app to save one baseline session now, compare monthly checkpoints later, and keep one clear record for your next treatment or dermatologist decision.

Start Tracking In BaldingAITry free tools or compare the app first

Why topical finasteride exists

Oral finasteride at 1mg daily reduces serum DHT by roughly 70%. That systemic suppression is what treats the hair follicles, but it also affects DHT levels throughout the body. In Merck's original phase III trials, 1.4% of men on finasteride reported decreased libido versus 0.9% on placebo. Erectile dysfunction was reported by 1.3% versus 0.7%. Those numbers are small in absolute terms, but they loom large in online forums and create real hesitation for men considering treatment.

The logic behind topical finasteride is straightforward: deliver the drug directly to scalp tissue where it can inhibit the type II 5-alpha reductase enzyme locally, while limiting how much enters the general circulation. If scalp DHT suppression is what regrows hair, and systemic DHT suppression is what drives side effects, then a topical formulation should be able to separate those two outcomes at least partially.

Interest accelerated after 2020 when compounding pharmacies made topical finasteride widely available and several clinical trials reported head-to-head comparisons. The result is a growing body of evidence that the topical route does reduce systemic exposure while preserving meaningful scalp activity.

How they compare: efficacy

The most cited head-to-head trial is Piraccini et al. (2022) published in the Journal of the American Academy of Dermatology. They compared topical 0.25% finasteride spray applied once daily against oral finasteride 1mg daily over 24 weeks. Both groups showed statistically significant improvement in hair count from baseline, and the difference between the two groups was not statistically significant. In practical terms, the topical formulation delivered comparable regrowth to the oral pill.

Earlier work by Caserini et al. (2014) in the Journal of Clinical Pharmacology provided the pharmacokinetic foundation. Their study showed that topical finasteride reduced scalp DHT by approximately 40% while oral finasteride reduced it by approximately 70%. Despite that difference in raw DHT suppression, hair regrowth outcomes were similar between the groups. The implication is that scalp tissue concentration matters more than total systemic DHT reduction for follicle recovery. You do not need to suppress DHT everywhere to get the follicles responding.

A 2023 meta-analysis by Lee et al. in Dermatologic Therapy pooled data from available controlled trials and confirmed that topical finasteride at concentrations between 0.1% and 0.25% produced hair density improvements that were not significantly different from oral 1mg. The confidence intervals overlap. For most men, the two forms produce functionally equivalent regrowth over a 6-to-12-month window.

How they compare: side effects

The side-effect profiles diverge in a predictable way. Oral finasteride carries the established 1-2% incidence of sexual side effects from the Merck phase III data: decreased libido, erectile dysfunction, and reduced ejaculatory volume. These effects are dose-dependent and reversible upon discontinuation in the vast majority of cases.

Topical finasteride shows lower rates of sexual side effects across available trials. The Piraccini study reported that serum DHT suppression was significantly lower in the topical group compared to the oral group, which correlates with the reduced systemic side-effect signal. Caserini et al. found that topical finasteride reduced serum DHT by only 25-30% versus the 70% reduction with oral, supporting the rationale that less drug reaches the bloodstream.

Topical finasteride does introduce a side effect that oral does not: scalp irritation. Approximately 5-10% of topical users report itching, dryness, or mild dermatitis at the application site. The vehicle (alcohol-based solutions are common) contributes to this. Switching to a different base or reducing application frequency can mitigate the problem for most users.

One honest caveat: topical finasteride is not zero-systemic. Some absorption always occurs through the scalp. The Caserini data show meaningful serum DHT reduction even with topical application. The reduction is smaller than oral, but it is not absent. Men who are extremely sensitive to any DHT change should discuss this with a dermatologist rather than assuming topical means no systemic effect at all.

Which one to choose

The choice comes down to three factors: side-effect tolerance, convenience, and treatment goals.

If side-effect concern is the primary driver, topical finasteride makes sense as a first-line option. The lower systemic DHT suppression translates to a lower probability of sexual side effects while still delivering clinically meaningful regrowth. For men who refused oral finasteride entirely due to side-effect anxiety, the topical form opens a door that was previously closed.

If convenience matters most, oral finasteride wins. One small pill per day with no scalp application, no drying time, no residue in your hair. Adherence tends to be higher with oral medications across most drug classes because the friction of daily topical application leads to skipped doses over time.

If maximum systemic DHT suppression is the goal (for example, if you also want body hair reduction or have prostate-related reasons for DHT control), oral finasteride delivers a more complete systemic effect. Topical concentrates the action at the scalp and is not designed to replace the systemic benefits of the oral form.

There is no wrong answer here. The right choice is the one you will actually take consistently for 12 or more months, because inconsistent use of either form produces poor results regardless of the route.

The tracking protocol for either form

Both oral and topical finasteride require patience. Hair follicles operate on a cycle measured in months, not days. The minimum evaluation window is 6 months, and most dermatologists recommend waiting 12 months before making a definitive judgment on response.

What to track monthly: standardized photos (same lighting, same angle, same distance, same hair state) of the hairline, crown, and any area of concern. A phone propped at a fixed height in the same bathroom is more reliable than handheld shots at varying angles. Photos taken in different conditions will mislead you into false optimism or false panic.

At month 3, expect shedding to have stabilized but visible regrowth to be minimal. Hair count data may show early stabilization. Do not interpret this checkpoint as success or failure. At month 6, early responders may notice reduced shedding, finer vellus hairs filling in, and improved density in photos. Non-responders typically show no change or continued loss. At month 12, you have enough data for a real assessment. Compare month-1 baseline photos to month-12 and look for density changes, hairline changes, and crown coverage shifts.

For topical users specifically, track scalp irritation as a separate data point. Log any itching, redness, or flaking weekly. If irritation worsens over time, that is a signal to discuss vehicle changes with your prescriber rather than a reason to abandon the medication entirely.

Switching between forms

Switching from oral to topical (or the reverse) is common and does not require a washout period. Finasteride's half-life is approximately 6 hours for oral administration, and the drug clears the system within days. You can transition directly from one form to the other.

Oral to topical is the more common switch direction, usually motivated by side-effect concerns. Expect a brief period where serum DHT levels rise as systemic suppression decreases and topical scalp concentration builds. Some users report a temporary increase in shedding during weeks 2-6 of the transition. This is not a sign that the topical version is failing. It reflects the adjustment in systemic versus local drug levels.

Topical to oral is less common but sometimes chosen for convenience or when a stronger systemic effect is desired. The transition is smoother in this direction because oral provides both systemic and scalp-level suppression. No shedding spike is typical.

In either case, mark the switch date in your tracking log and treat the first 3 months after switching as a new baseline period. Do not compare pre-switch photos directly to post-switch photos as if they are part of the same continuous timeline. The pharmacokinetics changed, so the comparison needs a reset.

Compounding pharmacies and formulations

Topical finasteride is not FDA-approved as a standalone product. There is no branded topical finasteride you can pick up at a retail pharmacy the way you would Propecia or generic oral finasteride. Most topical finasteride is prepared by compounding pharmacies, which mix the active ingredient into a topical vehicle according to a prescriber's specifications.

Common formulations range from 0.1% to 0.25% finasteride in an alcohol- or propylene-glycol-based solution, applied once daily via spray or dropper. Some compounding pharmacies combine finasteride with minoxidil in a single topical solution (often 0.1% finasteride with 5% or 6% minoxidil). This combination approach reduces the number of daily applications and can improve adherence for users who are on both medications.

Quality varies between compounding pharmacies. The concentration, vehicle composition, and stability of the preparation depend on the pharmacy's processes. Ask your prescriber about their preferred compounding pharmacy and whether they have verified the formulation's stability and absorption characteristics. Telehealth platforms like Hims, Happy Head, and Strut Health offer pre-formulated topical finasteride options with standardized concentrations, which removes some of the variability.

Cost is typically higher than generic oral finasteride. Oral generic finasteride runs $5-15 per month at most US pharmacies. Compounded topical finasteride ranges from $30-80 per month depending on the pharmacy and whether minoxidil is included. Insurance rarely covers compounded formulations. That price difference is worth factoring into a treatment plan you intend to maintain for years.

Track your topical or oral finasteride results month by month

BaldingAI gives you standardized photo checkpoints, side-effect logs, and adherence tracking so you can evaluate either form with real evidence instead of guesswork.

Use the BaldingAI hair tracking app to save one baseline session now, compare monthly checkpoints later, and keep one clear record for your next treatment or dermatologist decision.

Start Tracking In BaldingAITry free tools or compare the app first